The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The UK company buys IRDx for $1bn.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.